# Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia

> **NCT02871778** · PHASE2 · COMPLETED · sponsor: **Parion Sciences** · enrollment: 123 (actual)

## Conditions studied

- Primary Ciliary Dyskinesia

## Interventions

- **DRUG:** VX-371
- **DRUG:** Hypertonic Saline
- **DRUG:** Placebo (0.17% saline)
- **DRUG:** VX-371 + HS
- **DRUG:** Ivacaftor

## Key facts

- **NCT ID:** NCT02871778
- **Lead sponsor:** Parion Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2018-11-20
- **Final completion:** 2018-11-20
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2021-12-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02871778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02871778, "Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02871778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*